X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TransCon PTH
Therapeutic Area: Endocrinology Product Name: TransCon PTH
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
The primary endpoints of the study include evaluating the safety, tolerability and efficacy of once-daily subcutaneous injection of TransCon™ PTH in adults with HP.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TransCon PTH
Therapeutic Area: Endocrinology Product Name: TransCon PTH
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Ascendis Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
The multicenter, randomized, open-label and parallel control study aims to demonstrate noninferiority in annualized height velocity following weekly injections of TransCon hGH compared to once daily dosing of hGH after 52 weeks of treatment in prepubertal children with GHD.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TransCon hGH
Therapeutic Area: Endocrinology Product Name: TransCon hGH
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Sequoia China
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 09, 2021
Details:
Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
